Antibodies Targeted for Pan-Influenza Prophylaxis

A monoclonal antibody that mimics neuraminidase receptors provided protection against lethal influenza A and influenza B infections in a mouse model.

The prophylactic efficacy of monoclonal antibodies (mAbs) targeting SARS-CoV-2 represented a major therapeutic advance in the COVID-19 pandemic (NEJM JW Infect Dis May 4 2022 and N Engl J Med 2022; 386:2188; NEJM JW Gen Med Jan 2022). Now, researchers have provided evidence that similar prophylactic efficacy may be possible against influenza with the development of a mAb that targets the neuraminidase (NA) enzyme present on both influenza A and B.

Momont et al. created multiple mAbs using peripheral blood mononuclear cells from one healthy individual with high IgG anti-NA antibody titers. Three of these mAbs had broad neutralizing activity against a panel of influenza B viruses as well as influenza A H1N1 viruses; and two mAbs (FNI9 and FNI1…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Antibodies Targeted for Pan-Influenza Prophylaxis

Topics

Reviewing Author